Your browser is no longer supported. Please, upgrade your browser.
Settings
RNN Rexahn Pharmaceuticals, Inc. daily Stock Chart
RNN [NYSE]
Rexahn Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-5.28 Insider Own0.20% Shs Outstand4.05M Perf Week9.98%
Market Cap24.99M Forward P/E- EPS next Y-5.00 Insider Trans- Shs Float4.01M Perf Month-5.81%
Income-14.40M PEG- EPS next Q-1.00 Inst Own14.60% Short Float6.66% Perf Quarter-58.87%
Sales- P/S- EPS this Y52.70% Inst Trans56.72% Short Ratio1.25 Perf Half Y-56.43%
Book/sh3.48 P/B1.77 EPS next Y-14.70% ROA-81.30% Target Price94.50 Perf Year-68.84%
Cash/sh3.63 P/C1.70 EPS next 5Y- ROE-132.50% 52W Range4.75 - 28.56 Perf YTD-44.71%
Dividend- P/FCF- EPS past 5Y10.00% ROI- 52W High-78.40% Beta0.71
Dividend %- Quick Ratio5.00 Sales past 5Y- Gross Margin- 52W Low29.89% ATR0.65
Employees10 Current Ratio5.00 Sales Q/Q- Oper. Margin- RSI (14)45.90 Volatility15.20% 8.78%
OptionableYes Debt/Eq0.00 EPS Q/Q25.70% Profit Margin- Rel Volume0.46 Prev Close6.24
ShortableYes LT Debt/Eq0.00 EarningsMar 18 AMC Payout- Avg Volume214.09K Price6.17
Recom1.80 SMA20-4.18% SMA50-6.63% SMA200-54.58% Volume98,449 Change-1.12%
Apr-06-17Resumed Rodman & Renshaw Buy $2
Mar-20-15Initiated MLV & Co Buy $1.25
Dec-28-12Initiated Burrill Institutional Research Mkt Outperform $1
Jan-18-12Resumed Rodman & Renshaw Mkt Perform
Jun-16-11Resumed Brean Murray Buy $3
Dec-02-10Initiated Brean Murray Buy $3
Apr-16-19 01:05PM  China Licensing Deal Sends Nanocap Rexahn Pharma Rocketing Higher Benzinga +25.28%
08:00AM  Rexahn and BioSense Global Announce Collaboration and License Agreement for RX-3117 in Greater China GlobeNewswire
Apr-12-19 08:00AM  Rexahn Effects 1-for-12 Reverse Stock Split GlobeNewswire
Apr-10-19 04:07PM  Rexahn Announces Reverse Stock Split GlobeNewswire
Mar-27-19 08:00AM  Rexahn Announces Multiple Presentations at the 2019 American Association for Cancer Research Annual Meeting GlobeNewswire
Mar-08-19 08:00AM  Rexahn Pharmaceuticals Reports 2018 Financial Results GlobeNewswire
Mar-04-19 08:00AM  Rexahn Announces Target Enrollment Reached in Phase 2a Clinical Trial of RX-3117 in Combination With ABRAXANE® in First-line Metastatic Pancreatic Cancer Patients GlobeNewswire
Mar-01-19 08:00AM  Rexahn Pharmaceuticals Appoints Lara S. Sullivan to its Board of Directors GlobeNewswire
Feb-19-19 08:00AM  Rexahn Presents Updated Interim Data From Phase 2a Trial of RX-3117 in Advanced Bladder Cancer at the 2019 ASCO GU Symposium GlobeNewswire
Feb-15-19 02:04PM  What You Must Know About Rexahn Pharmaceuticals, Inc.s (NYSEMKT:RNN) Beta Value Simply Wall St.
Feb-06-19 08:00AM  Rexahn Announces Presentations at the 2019 ASCO Genitourinary Cancers Symposium GlobeNewswire
Feb-04-19 08:00AM  Rexahn Receives Notice of Allowance for U.S. Patent Covering RX-3117 Use in a Broad Range of Tumor Types GlobeNewswire
Jan-24-19 07:35AM  Market Trends Toward New Normal in SeaWorld Entertainment, Rigel Pharmaceuticals, Guidewire Software, Editas Medicine, Jones Energy, and Rexahn Pharmaceuticals Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Jan-23-19 09:00AM  Rexahn Announces Pricing of Public Offering of Common Stock and Warrants GlobeNewswire -39.11%
Jan-22-19 04:42PM  Rexahn Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire -19.20%
07:30AM  Rexahn Presents Updated Preliminary Data on RX-3117 in Pancreatic Cancer at the 2019 ASCO GI Symposium GlobeNewswire
Jan-18-19 07:49AM  The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug Benzinga -9.42%
Jan-16-19 09:00AM  Biotech Breaking Out ACCESSWIRE +5.88%
Jan-14-19 08:00AM  Rexahn Announces Presentation of RX-3117 Data at the 2019 ASCO Gastrointestinal Cancers Symposium GlobeNewswire +15.74%
Jan-13-19 03:50PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials Benzinga
Dec-11-18 07:25AM  Market Trends Toward New Normal in CME Group, Ambac Financial Group, Erie Indemnity, FuelCell Energy, Hovnanian Enterprises, and Rexahn Pharmaceuticals Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Dec-06-18 08:00AM  Rexahn Pharmaceuticals Streamlines Operations and Provides Update on Pipeline GlobeNewswire
Dec-03-18 08:00AM  Rexahn Pharmaceuticals Appoints Gil Price to its Board of Directors GlobeNewswire +5.56%
Nov-14-18 08:00AM  Rexahn Pharmaceuticals Announces Leadership Transition GlobeNewswire
Nov-05-18 08:00AM  Rexahn Reports Third Quarter 2018 Financial Results GlobeNewswire
Oct-17-18 09:00AM  Rexahn Announces $7.5 Million Registered Direct Offering GlobeNewswire -29.34%
Oct-15-18 08:00AM  New Research Coverage Highlights Cognex, Spirit Realty Capital, Quanta Services, Rexahn Pharmaceuticals, CNO Financial Group, and Hawaiian Electric Industries Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Oct-02-18 08:00AM  Rexahn Pharmaceuticals Presents Preliminary Safety and Efficacy Data From Ongoing Phase 2a Clinical Trial of RX-3117 in Combination With Abraxane® in Patients Newly Diagnosed With Metastatic Pancreatic Cancer GlobeNewswire
Sep-18-18 08:00AM  Rexahn Pharmaceuticals to Present at the 5th NCI Pancreatic Cancer Symposium GlobeNewswire +9.30%
Sep-05-18 11:35AM  Top Ranked Momentum Stocks to Buy for September 5th InvestorPlace
Aug-21-18 11:27AM  3 Marijuana Stocks & Biotech Stocks Capitalizing on Industry Momentum ACCESSWIRE +7.55%
08:00AM  Rexahn Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate RX-5902 (Supinoxin) in combination with KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer GlobeNewswire
Aug-08-18 08:00AM  Consolidated Research: 2018 Summary Expectations for First Foundation, CME Group, MetLife, D.R. Horton, Rexahn Pharmaceuticals, and 1st Source Fundamental Analysis, Key Performance Indications GlobeNewswire
Aug-07-18 08:00AM  Rexahn Issues Mid-Year Shareholder Letter to Review Recent Progress and Clinical Plans GlobeNewswire
Aug-06-18 08:00AM  Rexahn Reports Second Quarter 2018 Financial Results GlobeNewswire
Jul-31-18 03:16PM  Pluristem Therapeutics, Rexahn Pharma Are Biotech Winners, B Riley FBR Says In Bullish Initiation Benzinga +9.02%
Jun-14-18 10:00AM  Rexahn Announces Adjournment of Annual Meeting of Shareholders until Wednesday, June 27, 2018 GlobeNewswire
Jun-04-18 08:00AM  Rexahn Pharmaceuticals Announces Presentations at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting GlobeNewswire -8.14%
May-15-18 08:00AM  Rexahn Phase 2a Combination Study of RX-3117 and Abraxane® in First-line Metastatic Pancreatic Cancer Patients Advances to Second Stage GlobeNewswire
May-07-18 08:00AM  Rexahn Reports First Quarter 2018 Financial Results GlobeNewswire
May-03-18 07:50AM  Analysis: Positioning to Benefit within PTC, Black Hills, Mack-Cali Realty, Milacron, Rexahn Pharmaceuticals, and Sunoco LP Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Apr-26-18 08:00AM  Rexahn to Present Clinical Data at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire +7.50%
Mar-22-18 07:55AM  Research Report Identifies Westinghouse Air Brake Technologies, National Western Life Group, Impinj, Ingles Markets, RCI Hospitality, and Rexahn Pharmaceuticals with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Mar-13-18 08:00AM  Rexahn Pharmaceuticals to Present at Two Upcoming Conferences GlobeNewswire
Mar-12-18 08:00AM  Rexahn Pharmaceuticals Reports Full Year 2017 Financial Results GlobeNewswire
Feb-12-18 08:00AM  Rexahn Reports Data from the Ongoing Phase 2a Clinical Trial of RX-3117 in Advanced Bladder Cancer at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting GlobeNewswire
Feb-08-18 08:00AM  Rexahn Pharmaceuticals Announces Collaboration with Zhejiang Haichang Biotechnology Co., Ltd. for the Development of RX-0201 (Archexin®) for the treatment of Hepatocellular Carcinoma GlobeNewswire
Feb-05-18 08:00AM  Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting GlobeNewswire
Jan-29-18 10:07AM  Rexahn Pharmaceuticals, Inc. Secures First US Patent For Its Anticancer Drug Candidate SmarterAnalyst
08:00AM  Rexahn Pharmaceuticals Receives Notice of Allowance for A New U.S. Patent Covering the Use of RX-5902 (Supinoxin) GlobeNewswire
Jan-22-18 07:30AM  Rexahn Pharmaceuticals Announces Poster Presentation of RX-3117 Data in Metastatic Pancreatic Patients at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting GlobeNewswire
Jan-19-18 07:50AM  Consolidated Research: 2018 Summary Expectations for REGENXBIO, Rexahn Pharmaceuticals, QuinStreet, NewMarket, Stock Yards, and United States Lime & Minerals Fundamental Analysis, Key Performance Indications GlobeNewswire +13.74%
Jan-18-18 09:00AM  Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting GlobeNewswire
Jan-08-18 09:00AM  Rexahn Pharmaceuticals to Present at Biotech Showcase 2018 GlobeNewswire
Jan-04-18 09:00AM  Rexahn Pharmaceuticals Announces the Appointment of Douglas J. Swirsky as President and Chief Financial Officer GlobeNewswire +5.29%
Dec-11-17 09:00AM  Rexahn Pharmaceuticals Presents New Preclinical Data on Supinoxin at the 2017 San Antonio Breast Cancer Symposium GlobeNewswire
Nov-09-17 09:00AM  Rexahn Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference GlobeNewswire +6.09%
Nov-08-17 09:00AM  Rexahn Pharmaceuticals Doses First Patient in a Phase IIa Clinical Trial of RX-3117 in Combination with Abraxane® in Patients Newly Diagnosed with Metastatic Pancreatic Cancer GlobeNewswire +6.49%
Nov-07-17 08:00AM  Today's Research Reports on Trending Tickers: Rexahn Pharmaceuticals and Idera Pharmaceuticals ACCESSWIRE
Nov-06-17 09:11AM  Rexahn reports 3Q loss Associated Press
09:00AM  Rexahn Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
Oct-13-17 08:59AM  Rexahn Announces $8 Million Registered Direct Offering GlobeNewswire -23.59%
Oct-11-17 08:37AM  Rexahn Pharmaceuticals (RNN) in Focus: Stock Moves 6.1% Higher Zacks
Oct-10-17 09:00AM  Rexahn Pharmaceuticals Receives Positive Opinion from European Medicines Agency for Orphan Drug Designation for RX-3117 GlobeNewswire +6.12%
Sep-21-17 09:00AM  Rexahn Pharmaceuticals to Present at the 2017 Disruptive Growth Company Showcase NYC GlobeNewswire
Sep-11-17 08:15AM  Rexahn Pharmaceuticals Presents Final Data from the Supinoxin Phase I Clinical study and New Preclinical Data on RX-3117 at the 2017 European Society for Medical Oncology (ESMO) Congress GlobeNewswire
Sep-10-17 08:15AM  Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Advanced Bladder Cancer at the 2017 European Society for Medical Oncology (ESMO) Congress GlobeNewswire
Sep-06-17 09:00AM  Rexahn Pharmaceuticals to Present at 19th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire
Sep-05-17 09:00AM  Rexahn Pharmaceuticals to Present Updated Clinical and Preclinical Data at the 2017 European Society for Medical Oncology (ESMO) Congress GlobeNewswire +17.09%
Sep-01-17 09:00AM  Rexahn Pharmaceuticals Announces Retirement of its Founder, Chang Ahn, Ph.D., from the Board of Directors GlobeNewswire
Aug-30-17 09:00AM  Rexahn Pharmaceuticals Receives New U.S. Patent for Supinoxin GlobeNewswire -5.24%
08:00AM  Today's Research Reports on Trending Tickers: Rexahn Pharmaceuticals and Valeant Pharmaceuticals ACCESSWIRE
08:00AM  Rexahn, Pipeline Updates, Q2 Financial Review, Analysts Target Price ACCESSWIRE
Aug-14-17 09:00AM  Rexahn Pharmaceuticals Issues Mid-Year Shareholder Letter to Review Recent Progress and Clinical Plans GlobeNewswire
Aug-07-17 11:54PM  Rexahn posts 2Q profit Associated Press +6.52%
09:00AM  Rexahn Pharmaceuticals Reports Second Quarter 2017 Financial and Operational Results GlobeNewswire
Jul-10-17 09:00AM  Rexahn Pharmaceuticals Receives Notice of Allowance for a New U.S. Patent Covering the Use of RX-3117 GlobeNewswire
Jun-07-17 08:50AM  Rexahn Announces $10 Million Registered Direct Offering GlobeNewswire -15.17%
Jun-06-17 03:14PM  Rodman & Renshaw Encouraged on Rexahn Pharmaceuticals, Inc. (RNN) Following ASCO Update SmarterAnalyst
Jun-04-17 09:00AM  Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Bladder Cancer at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting GlobeNewswire
May-12-17 08:00AM  Today's Research Reports on Stocks to Watch: Rexahn Pharmaceuticals and Depomed Accesswire +7.30%
May-08-17 09:00AM  Rexahn Pharmaceuticals to Present RX-3117 Clinical Data at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting GlobeNewswire -7.27%
May-05-17 09:00AM  Rexahn Effects 1-for-10 Reverse Stock Split GlobeNewswire
May-04-17 09:44AM  Rexahn reports 1Q loss Associated Press
09:00AM  Rexahn Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
Apr-13-17 09:00AM  Rexahn Announces 1-for-10 Reverse Stock Split GlobeNewswire -26.14%
Mar-31-17 12:00PM  Penny Stocks to Watch for April 2017 (ATRS, WRN) Investopedia
12:00PM  Penny Stocks to Watch for April 2017 (ATRS, WRN) at Investopedia
Mar-28-17 09:30AM  BioDelivery Sciences International and Rexahn Pharmaceuticals See Share Values Rise Slightly Accesswire
Mar-16-17 09:30AM  Trade Volume Can Speak a Lot About Momentum of a Stock Accesswire
08:35AM  Rexahn Pharmaceuticals (RNN) Jumps: Stock Moves Up 5.4% Zacks
Mar-02-17 01:04PM  REXAHN PHARMACEUTICALS, INC. Financials
Feb-27-17 09:00AM  Rexahn Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Corporate Update GlobeNewswire
Feb-24-17 04:19PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
Feb-23-17 09:00AM  Rexahn Pharmaceuticals Doses First Patient in a Phase IIa Trial of Supinoxin in Patients with Metastatic Triple Negative Breast Cancer GlobeNewswire
Feb-06-17 09:00AM  Rexahn Pharmaceuticals to Present at the 2nd Annual Disruptive Growth & Healthcare Conference Accesswire
Jan-20-17 09:00AM  Rexahn Pharmaceuticals Presents an Update of the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Pancreatic Cancer at the American Society of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium GlobeNewswire
Jan-03-17 09:00AM  Rexahn Pharmaceuticals to Present at Biotech Showcase 2017 GlobeNewswire
Nov-25-16 04:04PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Shareholder Director Nominations
Nov-07-16 09:11AM  Rexahn reports 3Q loss
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's product pipeline include RX-3117, which is in Phase IIa clinical trials for the treatment of patients with relapsed or refractory metastatic pancreatic cancer, as well as bladder, colon, lung and cervical cancer; and RX-5902 that is in Phase IIa clinical trials to treat patients with metastatic triple negative breast cancer. It is also developing RX-0301, which is in preclinical development stage for the treatment of hepatocellular carcinoma. The company has collaboration agreements with Zhejiang Haichang Biotechnology Co., Ltd.; Merck Sharp & Dohme B.V.; and BioSense Global LLC. Rexahn Pharmaceuticals, Inc. is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nolan LisaChief Business OfficerFeb 28Option Exercise0.001,625023,250Mar 01 05:41 PM
Benaim ElyChief Medical OfficerFeb 28Option Exercise0.002,37504,750Mar 01 05:35 PM
Nolan LisaChief Business OfficerJan 30Buy0.6520,00012,96021,625Jan 31 07:48 AM
Swirsky Douglas JPresident and CEOJan 29Buy0.6350,00031,72050,000Jan 30 07:32 AM
Price Ben GilDirectorJan 29Buy0.6115,0009,14115,000Jan 31 07:56 AM